MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
PT-141 + Melanotan II Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
PT-141 (bremelanotide) and Melanotan II are structurally related cyclic heptapeptide melanocortin agonists derived from the same Hruby laboratory work on alpha-MSH analogs. Stacking them combines bremelanotide's MC4R-selective central libido activation, which is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women [PMID: 31764050], with Melanotan II's non-selective MC1R, MC3R, MC4R, and MC5R activity that drives cutaneous tanning. The supposed rationale is to get the libido benefit without losing the tanning effect, since PT-141 alone produces minimal pigmentation. The combination has no controlled human evidence, is not approved in any jurisdiction, and stacks the side-effect profiles of both peptides, especially nausea, transient blood pressure elevations from melanocortin tone, flushing, and nevus changes. Quality of grey-market product is highly variable.
Reconstitute: Add 3 mL bacteriostatic water → 3.33 mg/mL concentration.
Typical dose: On-demand subcutaneous use for sexual function; typical dose 1.75 mg (1750 mcg) administered ≥45 min before activity[1].
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL = 0.0333 mg (33 mcg) on a U-100 insulin syringe.
Storage: Lyophilized frozen at −20 °C; reconstituted refrigerated at 2–8 °C.
MC4R overlap drives side effects: Both peptides hit MC4R, so combining them roughly doubles MC4R exposure. Expect compounded nausea, blood pressure elevations of around 6 mmHg systolic, and flushing, especially in the first 2 to 4 hours.
Pigmentation tradeoff: MT-II is the active tanning component because PT-141 has weak MC1R affinity. Users targeting libido alone usually do not need MT-II; stacking is mostly cosmetic-driven and adds melanoma surveillance concerns.
Approved component vs unapproved component: Bremelanotide is FDA-approved as Vyleesi (women) for HSDD. MT-II is not approved anywhere. Any stacked protocol falls outside the Vyleesi label and is unsupported by safety data.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming or direct impact on the powder.
Gently swirl or roll until fully dissolved (do not shake).
Inject slowly; wait a few seconds before withdrawing the needle.
Aspiration is not required for subcutaneous injections; inject slowly and steadily[8].
Interactive PT-141 + Melanotan II Syringe Calculator
Currently visualizing the 10 mg + 10 mg vial reconstituted with 3 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 10mg dry powder in 3mL water yields 3.33 mg/mL. To evaluate a 250mcg dose, pull to 7.5 units (8 syringe ticks).
U-100 Syringe Representation
7.5 Units (8 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Initial / Titration | 500–750 mcg | 15–22 units (0.15–0.22 mL) |
| Standard | 1000–1500 mcg | 30–45 units (0.30–0.45 mL) |
| Full / FDA-Approved | 1750 mcg (1.75 mg) | 52 units (0.52 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 250 mcg | 7.5 units (0.075 mL)* |
| Week 2 | 500 mcg | 15 units (0.15 mL) |
| Weeks 3–4 | 750 mcg | 22 units (0.22 mL) |
| Weeks 5+ (Loading) | 1000 mcg | 30 units (0.30 mL) |
| Maintenance | 500–1000 mcg (2–3×/week) | 15–30 units (0.15–0.30 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 10 mg + 10 mg vial.
Peptide Vials (PT-141, 10 mg each):
- check8 weeks: 2 vials
- check12 weeks: 3 vials
- check16 weeks: 4 vials
Insulin Syringes (U-100):
- check8 weeks: 8 syringes
- check12 weeks: 12 syringes
- check16 weeks: 16 syringes
Bacteriostatic Water (10 mL bottles):
- check8 weeks (2 vials × 3 mL): 1 bottle
- check12 weeks (3 vials × 3 mL): 1 bottle
- check16 weeks (4 vials × 3 mL): 2 bottles
Mechanism of Action (MOA)
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH) that differs from Melanotan II only by lacking the C-terminal amide and is, in fact, a metabolite of MT-II identified during the Phase I clinical program at the University of Arizona. The structural difference is small but has substantial pharmacological consequences: PT-141 binds MC3R and MC4R with high affinity while having significantly reduced activity at MC1R, the melanocyte receptor responsible for tanning. As a result, PT-141 produces robust central effects on sexual desire and erection but minimal pigmentation, making it suitable as a pharmaceutical sexual-dysfunction therapeutic [1]. Melanotan II, by contrast, is broadly non-selective across MC1R, MC3R, MC4R, and MC5R, producing both cosmetic tanning and centrally mediated sexual effects, along with appetite suppression, autonomic activation, and exocrine gland stimulation. The mechanistic rationale for combining the two peptides is to use MT-II to establish persistent cutaneous pigmentation (which requires MC1R activation) while reserving PT-141 for acute pre-coital use to produce predictable on-demand sexual response without further pigmentation drift. In the central nervous system, MC4R agonism in the medial preoptic area and paraventricular nucleus of the hypothalamus drives pro-erectile signaling through downstream oxytocin and nitric oxide pathways, while MC3R activation in mesolimbic dopaminergic circuits enhances sexual motivation. The FDA-approved label for Vyleesi (PT-141 1.75 mg SC) recommends administration at least forty-five minutes before sexual activity, with peak central effects between thirty and ninety minutes and durations of four to six hours [2]. When used in a stack, MT-II is typically dosed during a loading phase (0.10–0.25 mg subcutaneously, titrated up to 0.5–1 mg every one to three days alongside ultraviolet exposure) to develop tan, followed by maintenance dosing (similar doses one to two times per week) to preserve pigmentation. PT-141 is dosed acutely (0.5–1.75 mg subcutaneously) before sexual activity, no more than once per twenty-four hours and no more than eight times per month according to the Vyleesi label. Some users adjust PT-141 dosing downward when MT-II is concurrently active, since both peptides activate overlapping MC3R/MC4R signaling and side effects may be additive. Despite the apparent pharmacological logic of separating cosmetic and sexual effects between two peptides, the combined regimen has not been studied in formal clinical trials. The FDA-approved label for Vyleesi does not address concurrent melanocortin agonist use, and the safety database for chronic Melanotan II use is essentially limited to case reports and small observational series. The combination therefore amplifies all the side effects of melanocortin agonism—nausea, flushing, yawning, headache, transient blood pressure elevations, spontaneous erections, and skin hyperpigmentation—and inherits the long-term oncologic and dermatologic concerns associated with MT-II, including documented case reports of new and darkening nevi and isolated melanomas in users [3]. Stacking therefore constitutes a risk-amplifying combination rather than a complementary strategy, and major regulators have not endorsed concurrent use.
Clinical Trial Efficacy Highlights
- starPT-141 received FDA approval in 2019 as Vyleesi (bremelanotide injection 1.75 mg) for hypoactive sexual desire disorder in premenopausal women based on the RECONNECT Phase III program, which demonstrated significant improvements in desire and distress scores compared with placebo with manageable safety, establishing the clinical efficacy of acute MC3R/MC4R agonism for sexual response [1].
- starDiamond, Earle, Rosen and colleagues conducted multiple double-blind, placebo-controlled trials of subcutaneous bremelanotide in men with erectile dysfunction unresponsive to PDE5 inhibitors, documenting dose-dependent improvements in erection and intercourse success rates and characterizing the central mechanism distinct from peripheral vasoactive therapy [4].
- starWessells and colleagues' foundational human studies of Melanotan II established that melanocortin agonism produces penile erection and increased sexual desire independent of erotic stimuli, providing the proof-of-concept that underlies both PT-141's development as a pharmaceutical and the contemporary use of MT-II in off-label sexual-function protocols [5].
- starPharmacokinetic studies of PT-141 indicate rapid subcutaneous absorption with peak plasma concentrations at thirty to ninety minutes and an elimination half-life around two hours, while MT-II demonstrates much greater metabolic stability and prolonged tissue retention, supporting the rationale that combining the two peptides could deliver both sustained pigmentation and acute, time-limited sexual effects [2].
- starCase series and observational data from sexual-medicine practices indicate that MC3R/MC4R activation can rescue sexual response in patients refractory to PDE5 inhibitors, but combining acute PT-141 dosing with concurrent MT-II use has not been formally evaluated in controlled trials, and the magnitude of any additive benefit beyond PT-141 alone is unknown [3].
- starDermatologic case reports document accelerated appearance of new pigmented nevi, darkening of existing nevi, and rare melanomas in patients using Melanotan II for tanning purposes, raising the oncologic risk profile of any stack that includes MT-II and limiting the long-term safety case for the combined regimen [3].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningNausea is the most common adverse effect of both peptides and is amplified when they are combined, particularly with the first one or two doses; it typically peaks thirty to ninety minutes after injection and improves with gradual titration and concurrent food intake.
- warningFacial flushing, yawning, fatigue, headache, and transient elevation of blood pressure and heart rate are reported with both peptides individually and may be additive when combined, especially with higher PT-141 doses.
- warningSpontaneous penile erection in men and increased genital arousal in both sexes can be useful in the sexual-medicine context but may be inconvenient, embarrassing, or in rare cases prolonged; priapism has been reported with melanocortin agonists.
- warningSkin hyperpigmentation including darkening of moles, freckles, lips, areolae, and palmar creases is driven primarily by the MT-II component; the addition of PT-141 does not substantially alter pigmentation but may slightly prolong overall melanocortin exposure.
- warningCase reports describe new pigmented nevi, dysplastic nevi, and rare melanomas in Melanotan II users; these dermatologic concerns persist in any stack that includes MT-II and are not mitigated by combining with PT-141.
- warningPT-141 carries a labeled risk of transient blood pressure elevation and is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease; the same precautions apply when stacking with MT-II.
- warningSafety in pregnancy, lactation, and adolescents is not established, and the combination should be avoided in patients with personal or family history of melanoma, multiple atypical nevi, or significant cardiovascular risk.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical PT-141 and Melanotan II dosage?expand_more
Research protocols typically use MT-II 0.25–1 mg subcutaneously during a loading phase (every 1–3 days with UV exposure) then maintenance 1–2 times weekly, plus PT-141 0.5–1.75 mg subcutaneously as needed at least 45 minutes before sexual activity, no more than once per 24 hours.
How is the PT-141 and Melanotan II stack administered?expand_more
Both peptides are administered subcutaneously into the abdomen using an insulin syringe after reconstitution of lyophilized peptide with bacteriostatic water. Doses are typically given at separate times: MT-II on a scheduled tanning protocol, PT-141 on demand before sexual activity.
Can PT-141 and Melanotan II be combined with other compounds?expand_more
Both peptides should be used with caution if combined with PDE5 inhibitors, antihypertensives, MAO inhibitors, or stimulants, due to additive cardiovascular effects. Combining with additional melanocortin agonists or with significant UV exposure increases dermatologic and cardiovascular risk.
What are the side effects of the PT-141 and Melanotan II stack?expand_more
Common effects are nausea, flushing, yawning, fatigue, headache, transient blood pressure elevation, spontaneous erections, and skin hyperpigmentation. Long-term dermatologic risks include new and darkening nevi and rare melanoma case reports linked to MT-II.
Is the PT-141 and Melanotan II stack FDA approved?expand_more
PT-141 (bremelanotide) is FDA approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women at a specific dose. Melanotan II is not approved for any indication. The combination of the two peptides has never been evaluated or approved by any regulator.
Academic References & Study Citations
Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908. View Scientific Paper →
Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16(1):51-59. View Scientific Paper →
Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology. 2014;228(1):34-36. View Scientific Paper →
Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004;16(2):135-142. View Scientific Paper →
Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000;12 Suppl 4:S74-S79. View Scientific Paper →
Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-1784. View Scientific Paper →
Pfaus J, Giuliano F, Gelez H. Bremelanotide: an overview of preclinical CNS effects on female sexual function. J Sex Med. 2007;4 Suppl 4:269-279. View Scientific Paper →
Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016;12(3):325-337. View Scientific Paper →
Langan EA, Nie Z, Rhodes LE. Melanotropic peptides: more than just 'Barbie drugs' and 'sun-tan jabs'? Br J Dermatol. 2010;163(3):451-455. View Scientific Paper →